We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+20.87%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$257M
AUM Growth
+$32.7M
Cap. Flow
+$1.11M
Cap. Flow %
0.43%
Top 10 Hldgs %
99.62%
Holding
17
New
1
Increased
1
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ENLV icon
Enlivex Ltd
ENLV
+$2.76M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.28M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$2.97M
2
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$819K
3
AKTX
Akari Therapeutics
AKTX
+$78K
4
ECTE
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
+$62K

Sector Composition

Rank Sector Weight
1 Healthcare 13.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$222M 86.32%
4,489,038
-70,000
-2% -$2.97M
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$12M 4.67%
11,236
+1,355
+14% +$2.28M
ARCT icon
3
Arcturus Therapeutics
ARCT
$157M
$10.6M 4.13%
98,143
– –
KERX
4
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.75M 1.07%
200,000
– –
ENLV icon
5
Enlivex Ltd
ENLV
$70.7M
$2.46M 0.96%
+564
New +$2.76M
TOVX icon
6
Theriva Biologics
TOVX
$10.2M
$2.39M 0.93%
155
– –
LUMO
7
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.66M 0.65%
8,604
– –
INO icon
8
Inovio Pharmaceuticals
INO
$79.8M
$1.01M 0.39%
8,507
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$756K 0.29%
15,000
– –
GLMD icon
10
Galmed Pharmaceuticals
GLMD
$3.94M
$559K 0.22%
361
– –
NWBO
11
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$337K 0.13%
67,035
-133,265
-67% -$819K
NRX
12
DELISTED
NEPHROGENEX INC COM
NRX
$234K 0.09%
50,000
– –
PVCT
13
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$204K 0.08%
200,000
– –
ADXSW
14
DELISTED
Advaxis Inc Warrants
ADXSW
$162K 0.06%
112,500
– –
CLRB icon
15
Cellectar Biosciences
CLRB
$19.3M
– –
0
– –
AKTX
16
Akari Therapeutics
AKTX
$15.2M
– –
-2
Closed -$78K
ECTE
17
DELISTED
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
– –
-27,430
Closed -$62K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Knoll Capital Management held 17 positions worth $257M, up 15% from $224M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Knoll Capital Management's Q3 2014 filing shows 1 new, 1 increased, 2 reduced and 2 closed positions. Its largest new stake was Enlivex Ltd: 564 shares worth $2.46M. The largest sale was MEDIVATION, INC., an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 21% a quarter earlier.

  • Knoll Capital Management's largest Q3 2014 buy was Enlivex Ltd: 564 shares worth $2.46M.
  • Knoll Capital Management added most to Ampio Pharmaceuticals Inc. in Q3 2014, an estimated $2.28M increase.
  • Knoll Capital Management's biggest Q3 2014 reduction was MEDIVATION, INC., cutting an estimated $2.97M.
  • Knoll Capital Management fully exited Akari Therapeutics in Q3 2014, selling an estimated $78K.
  • Knoll Capital Management's ten largest holdings make up 100% of its $257M portfolio in Q3 2014.
  • Knoll Capital Management opened 1 new position and closed 2 in Q3 2014.
  • Knoll Capital Management's portfolio value rose 15% quarter-over-quarter to $257M.

Based on Knoll Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.